New Proteomics US testing lab opens door to vast diagnostic market

Proteomics International Laboratories can now roll out its precision diabetes-related blood test into the lucrative United States diagnostics market, after receiving certification for its California-based reference laboratory.

Certification of the lab, based in the healthcare precinct of Irvine, allows Proteomics to offer its clinical laboratory services in any US States that recognise the certification.

Proteomics International Laboratories has opened a new laboratory in the United States, certified by the State of California, to roll out its novel PromarkerD kidney disease test.

It will allow the company to offer a range of novel blood tests direct to patients, starting with its flagship PromarkerD predictive test for diabetes-related chronic kidney disease.

PromarkerD is approved to identify diabetes patients at risk of developing kidney disease up to four years in advance. Improved patient outcomes from an early test will likely save a big chunk of the estimated $130 billion annual healthcare cost of the disease, which affects 32 million adults in the US.

After PromarkerD is bedded down, Proteomics will then introduce other diagnostic solutions from the company’s pipeline through its Irvine facility, including PromarkerEso for oesophageal cancer and PromarkerEndo for the debilitating condition endometriosis.

“This achievement is testament to the technical expertise and drive of our team to bring our potentially life-changing tests to patients in the US. We see enormous market potential immediately for PromarkerD, and subsequently PromarkerEso and PromarkerEndo, to improve patient lives and save the US healthcare system millions of dollars.”

Proteomics International managing director Dr Richard

Proteomics entry into the US is expected to drive significant revenue growth for the business on the back of the health sector’s increasing focus on early disease detection and personalised medicine.

Precision diagnostics is one of the most lucrative up-and-coming healthcare markets in the world and is projected to be worth more than $100b by 2030. Diabetes-related diagnostics will play a major part in that growth.

Proteomics plans to initially introduce PromarkerD through a direct-to-consumer and direct-to-patient distribution model, setting the stage for potential licensing deals with major diagnostic industry players.

The scalability of the Irvine laboratory is another key advantage as it offers a cost-effective path to market penetration. The facility mirrors the company’s existing operations in Perth, allowing for a smooth roll out of its diagnostic platform while allowing for future expansion as demand for its products grows.

With an established certified laboratory and a clear commercialisation strategy, Proteomics International appears well-positioned to capitalise on an emerging healthcare trend.

Punters will, no doubt, be keeping an eye out for further news of licensing agreements, adoption rates and potential partnerships. Nailing down any - or all three - of those milestones could cement Proteomics’s position as a key player in the precision diagnostics space.

Is your ASX-listed company doing something interesting? Contact: [e-mail]